RxDoctor Payments Data

Ginger Shupe, MD

Psychiatry · South Miami, FLNPI 1689931115

Payments from drug & device makers

$47,323in general payments, 2019–2025

Across 286 payments — averaging $165.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Axsome Therapeutics, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$881
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$11,31024%
  • Speaking & faculty fees$24,70052%
  • Travel & lodging$2,4235%
  • Food & beverage$8,67318%
  • Education$2170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,323 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$29,738
Medicare patients
75
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$182,593
Abilify MaintenaAripiprazole29$92,147
NuplazidPimavanserin Tartrate17$85,339
Invega SustennaPaliperidone Palmitate23$64,752
AristadaAripiprazole Lauroxil17$58,969
VraylarCariprazine Hcl26$40,166
LybalviOlanzapine/Samidorphan Malate17$25,957
AuvelityDextromethorphan Hbr/Bupropion28$23,189
RexultiBrexpiprazole15$22,108
Aripiprazole199$19,185
NamzaricMemantine Hcl/Donepezil Hcl15$13,460
TrintellixVortioxetine Hydrobromide22$10,759
Clozapine111$8,462
Divalproex Sodium266$5,548
Mirtazapine392$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,370$182,59323 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$881$114,25644 claims
Alkermes, Inc.Aristada, Lybalvi$345$84,92634 claims
Johnson & JohnsonInvega Sustenna$312$64,75223 claims
AbbVieVraylar, Namzaric$26,952$53,62741 claims
Axsome Therapeutics, Inc.Auvelity$1,906$23,18928 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$207$10,75922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →